Siga Technologies INC Accounts Receivable, Allowance for Credit Loss
Siga Technologies INC (SIGA) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-03-10
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2024-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2023-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2022-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-10 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-10 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-11 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-12 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-03 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |